Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming

Executive Summary

Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.

You may also be interested in...



More Like Untouchable? US Medicare ‘Protected Classes’ Stay Protected – Again

A decision made more than 15 years ago by CMS to require drug insurance plans to cover all drugs for six specific diseases has proven impervious to change. But will the protected classes remain if Part D is reformed more broadly?

Becerra Takes The Helm At HHS; More Visibility On Administration’s Drug Pricing Priorities To Follow

Becerra’s HHS has a new crop of former Capitol Hill staffers in its policy ranks who are well versed on legislation in the health care realm, including prescription drug pricing reform. That will help advance the Administration’s agenda.

Biden Offers American Exceptionalism In Vaccine Development During COVID Anniversary Speech

Conveniently omitting Germany’s BioNTech, the US president says ‘development, manufacture, and distribution of the vaccines in record time is a true miracle of science. It is one of the most extraordinary achievements any country has ever accomplished.’

Related Content

Topics

UsernamePublicRestriction

Register

PS143883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel